BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25293521)

  • 1. The XIAP inhibitor Embelin enhances TRAIL-induced apoptosis in human leukemia cells by DR4 and DR5 upregulation.
    Hu R; Yang Y; Liu Z; Jiang H; Zhu K; Li J; Xu W
    Tumour Biol; 2015 Feb; 36(2):769-77. PubMed ID: 25293521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Embelin sensitizes acute myeloid leukemia cells to TRAIL through XIAP inhibition and NF-κB inactivation.
    Yang T; Lan J; Huang Q; Chen X; Sun X; Liu X; Yang P; Jin T; Wang S; Mou X
    Cell Biochem Biophys; 2015 Jan; 71(1):291-7. PubMed ID: 25358405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
    Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
    J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Embelin on TRAIL receptor 2 mAb-induced apoptosis of TRAIL-resistant A549 non-small cell lung cancer cells.
    Jiang L; Hao JL; Jin ML; Zhang YG; Wei P
    Asian Pac J Cancer Prev; 2013; 14(10):6115-20. PubMed ID: 24289635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor Effects of IL-1β Induced TRAIL-Expressing hUCMSCs on Embelin Treated Breast Cancer Cell Lines.
    Teng JW; Hung E; Wu JM; Liang YH; Chiu YH; Tyan YS; Wang HS
    Asian Pac J Cancer Prev; 2023 Apr; 24(4):1297-1305. PubMed ID: 37116152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP.
    Siegelin MD; Gaiser T; Siegelin Y
    Neurochem Int; 2009 Nov; 55(6):423-30. PubMed ID: 19409438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
    Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
    Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin-mediated c-myc overexpression and cytochrome c (cyt c) release result in the up-regulation of the death receptors DR4 and DR5 and the activation of caspase 3 and caspase 9, likely responsible for the TRAIL-sensitizing effect of cisplatin.
    Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
    Med Oncol; 2015 Apr; 32(4):133. PubMed ID: 25796504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R; Porosnicu M; Nguyen D; Worthington E; O'Bryan E; Perkins C; Bhalla K
    Clin Cancer Res; 2001 Feb; 7(2):350-7. PubMed ID: 11234890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XIAP antagonist embelin inhibited proliferation of cholangiocarcinoma cells.
    Wehrkamp CJ; Gutwein AR; Natarajan SK; Phillippi MA; Mott JL
    PLoS One; 2014; 9(3):e90238. PubMed ID: 24603802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic apoptosis of human gastric cancer cells by bortezomib and TRAIL.
    Bui HTT; Le NH; Le QA; Kim SE; Lee S; Kang D
    Int J Med Sci; 2019; 16(11):1412-1423. PubMed ID: 31673231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells.
    Kauntz H; Bousserouel S; Gossé F; Raul F
    Apoptosis; 2012 Aug; 17(8):797-809. PubMed ID: 22555452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
    Strekalova E; Malin D; Rajanala H; Cryns VL
    Breast Cancer Res Treat; 2017 Jun; 163(3):435-447. PubMed ID: 28324269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells.
    Allensworth JL; Aird KM; Aldrich AJ; Batinic-Haberle I; Devi GR
    Mol Cancer Ther; 2012 Jul; 11(7):1518-27. PubMed ID: 22508521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.
    Nathwani SM; Greene LM; Butini S; Campiani G; Williams DC; Samali A; Szegezdi E; Zisterer DM
    Int J Oncol; 2016 Jul; 49(1):74-88. PubMed ID: 27176505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.
    Bychkov ML; Gasparian ME; Dolgikh DA; Kirpichnikov MP
    PLoS One; 2014; 9(10):e109756. PubMed ID: 25310712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
    Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells.
    Yano K; Horinaka M; Yoshida T; Yasuda T; Taniguchi H; Goda AE; Wakada M; Yoshikawa S; Nakamura T; Kawauchi A; Miki T; Sakai T
    Int J Oncol; 2011 Feb; 38(2):365-74. PubMed ID: 21165560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAPE promotes TRAIL-induced apoptosis through the upregulation of TRAIL receptors via activation of p38 and suppression of JNK in SK-Hep1 hepatocellular carcinoma cells.
    Kim EY; Ryu JH; Kim AK
    Int J Oncol; 2013 Oct; 43(4):1291-300. PubMed ID: 23857473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.